Treatments for idiopathic pulmonary fibrosis: To the editor [2]

New England Journal of Medicine

Volumn 371, Issue 8, 2014, Pages 782-

  Thabut, Gabriel ^a   Crestani, Bruno ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; PLACEBO; ANTIFIBRINOLYTIC AGENT; ENZYME INHIBITOR; PYRIDONE DERIVATIVE;

DISEASE COURSE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; LETTER; LUNG TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT FAILURE; FEMALE; MALE; NOTE;

ANTIFIBRINOLYTIC AGENTS; ENZYME INHIBITORS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; PYRIDONES;

EID: 84906920660     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1407776     Document Type: Letter

References (3)

1. Lawrence Gould A, Boye ME, Crowther MJ, et al. Joint modeling of survival and longitudinal non-survival data: current methods and issues: report of the DIA Bayesian joint modeling working group. Stat Med 2014 March 14 (Epub ahead of print).
2. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009;374:222-8.
3. Nobel PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9.